Loading...
Loading...

Go to the content (press return)

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

Author
Poveda, E.; Hernández, J.; Perez, M.J.; Ribas, M.; Martínez, O.; Flores, J.; Navarro, J.; Gutiérrez, F.; García, M.; Imaz, A.; Ocampo, A.; Artero, A.; Blanco, F.; Bernal, E.; Pasquau, J.; Mínguez, C.; Perez, N.; Aiestaran, A.; García, F.; Paredes, R.
Type of activity
Journal article
Journal
HIV medicine
Date of publication
2017-08-01
Volume
18
Number
7
First page
482
Last page
489
DOI
https://doi.org/10.1111/hiv.12479 Open in new window
URL
http://onlinelibrary.wiley.com/doi/10.1111/hiv.12479/abstract;jsessionid=CD4AD5BC7CDA32D275BD424E924AB992.f03t04 Open in new window
Abstract
Objectives Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue. Methods PROTEST was a phase 4, prospective, single-arm clinical trial carried out in 24 HIV care centres in Spain. MVC-naïve HIV-1-infected patients with ...
Keywords
Maraviroc, genotypic tropim, proviral DNA
Group of research
GRBIO - Biostatistics and Bioinformatics Research Group

Participants

  • Poveda, E.  (author)
  • Hernández Quero, José  (author)
  • Perez Elias, M. Jesus  (author)
  • Ribas, M. A.  (author)
  • Martínez Madrid, O. J.  (author)
  • Flores, J.  (author)
  • Navarro, J.  (author)
  • Gutiérrez, F.  (author)
  • García Deltoro, M.  (author)
  • Imaz, Arkaitz  (author)
  • Ocampo, A.  (author)
  • Artero, A.  (author)
  • Blanco, F.  (author)
  • Bernal, Enrique  (author)
  • Pasquau, J.  (author)
  • Mínguez Gallego, C.  (author)
  • Perez Alvarez, Nuria  (author)
  • Aiestaran, A.  (author)
  • García, F.  (author)
  • Paredes, Raul  (author)